Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021831 (enteropathy)
 4,403 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Salinomycin (SAL), an ionophorous polyether antibiotic with growth promoter properties in pigs, has proved to be effective in controlling swine dysentery, porcine intestinal adenomatosis, and porcine haemorrhagic enteropathy. This study examines the ability of SAL to control C. perfringens type-A infection in growing pigs under field conditions. For 2 months, two groups of weaned pigs were offered feed either free of antibiotics, or medicated with 60 ppm and 30 ppm SAL for the first and second month respectively, and were compared with regard to their performance. The results showed that, whilst treatment did not have an effect on the mortality of pigs, the duration of pig diarrhoea during the trial period has been markedly reduced in the SAL group. Laboratory examinations have additionally shown that the number of carrier piglets has been reduced by SAL medication. Finally, treated pigs gained more weight and had a better feed-conversion ratio than untreated pigs during the 2-month trial period. It was concluded that SAL at the registered dose range, used as performance enhancer, can be helpful in controlling C. perfringens type-A infection in growing pigs.
 ...
PMID:The effect of salinomycin on the control of Clostridium perfringens type-A infection in growing pigs. 857 15

The aim of this study was to evaluate the effect of different antibiotics used as growth promoters on the control of porcine intestinal adenomatosis when administered in weaning, growing and fattening pig diets, according to Annex I of the European Union directive (70/524/EEC and its subsequent amendments to date) for the use of feed additives. On a farm with a previous history of proliferative enteropathy outbreaks, 648 weaned piglets (23 days old) were divided into nine experimental groups according to bodyweight and sex ratio, each group comprising four pens with 18 pigs in each pen. One group served the trial as a negative (unmedicated) control: another (the positive control) received monensin via feed at 100 p.p.m. up to the end of the growing phase (107 days old) and 50 p.p.m. up to slaughter age (156 days old). The remaining seven groups were offered feed with the addition of the following antibiotics: virginia-mycin (50-20 p.p.m.), avilamycin (40-20 p.p.m.), spiramycin (50-20 p.p.m.), zinc bacitracin (50-10 p.p.m.), avoparcin (40-20 p.p.m.), tylosin (40-20 p.p.m.) and salinomycin (60-30 p.p.m.), respectively. The performance of the pigs in the positive control group was very satisfying and among the highest in the trial, verifying earlier field studies. As a general conclusion it seems that all tested growth promoters had a beneficial effect compared with the untreated control, indicated by the decrease of mortality rate, the elimination of diarrhoeal incidence and the enhancement of growth performance, although the proliferative enteropathy control achieved by each substance was not always satisfactory. More specifically, the antibiotic growth promoters tested can be scaled according to their total efficacy as follows: 1. Salinomycin, tylosin, spiramycin; 2. Virginiamycin, zinc bacitracin, avilamycin; and 3. Avoparcin. Finally, it is considered that part of the growth promotion efficacy of the tested substances is due to their potential capacity to control porcine intestinal adenomatosis; thus, in future growth performance trials, the disease background of the trial farms must be examined, especially for porcine enteropathy challenges.
 ...
PMID:Control of proliferative enteropathy in growing/fattening pigs using growth promoters. 955 33